RASTEM: Stem Cell Innovation for Rheumatoid Arthritis Research

Quick answer

RASTEM is an autologous adipose-derived mesenchymal stem cell product currently under clinical trial preparation by EHL BIO for Rheumatoid Arthritis management. It focuses on utilizing stem cells' immunomodulatory properties to balance the immune system and reduce chronic joint inflammation.

Key takeaways

RASTEM is an autologous adipose-derived mesenchymal stem cell therapy.
Patented for its composition specifically designed for Rheumatoid Arthritis management.
Aims to balance Th1 and Th2 T-cells to reduce autoimmune responses as evaluated by the EHL team.
Developed under GMP standards within Class 100 cleanroom facilities.

Understanding RASTEM and Its Mechanism

RASTEM is a core innovation from EHL BIO, currently in the research and development (R&D) phase as a stem cell-based drug for Rheumatoid Arthritis. The product utilizes Mesenchymal Stem Cells (MSCs) extracted from the patient's own adipose tissue (autologous), which offers high safety profiles and minimizes the risk of immune rejection as evaluated by the EHL team.

Biologically, Rheumatoid Arthritis is primarily caused by an immune system imbalance, specifically between Th1 and Th2 T-cells, leading the body to attack its own joint tissues. The stem cells in RASTEM possess immunomodulatory properties, helping to suppress excessive immune responses and promote the repair of damaged tissues. This is achieved through the 'Homing Effect,' the natural ability of stem cells to migrate toward sites of inflammation to initiate the regeneration process.

Research Progress and Patents

EHL BIO prioritizes scientific validation; RASTEM has officially received a patent for its composition effective in managing Rheumatoid Arthritis. This achievement stems from the collective expertise of over 85 researchers and rigorous laboratory testing. The patent reinforces EHL BIO's leadership in developing targeted regenerative medicine.

Beyond RASTEM, EHL BIO has published research regarding stem cell applications in autoimmune and inflammatory conditions, which share similar mechanisms in T-cell regulation. Securing this patent is a significant milestone, preparing the foundation for upcoming clinical trials. These trials aim to support the efficacy of RASTEM in joint recovery and the restoration of quality of life.

RASTEM represents EHL BIO's commitment to transforming research into reality, supporting mobility for Rheumatoid Arthritis patients.

GMP Production Standards

The quality of RASTEM begins with high production standards. EHL BIO operates within GMP (Good Manufacturing Practices) facilities and was licensed as a Human Cell Management Business in Korea. Our facilities feature Class 100 cleanrooms and HEPA filtration systems to ensure that cultured stem cells remain at a high purity level.

EHL BIO’s proprietary cell culture technology allows for high cell yields while maintaining exceptional cell viability. Our comprehensive cell banking system, utilizing cryogenic storage at -196°C, enables patients to preserve their high-quality cells for continuous rehabilitation as planned by the EHL medical team. We possess a production capacity of 6,000 lots per year.

Restoring Quality of Life with EHL Thailand

For patients in Thailand, EHL Thailand provides a professional coordination team guiding you through the 6-step care process. It begins with an online consultation, which is forwarded to Korean specialists for document evaluation and personalized planning. Patients then travel to the EHL Cell Clinic in Korea for cell collection.

EHL BIO’s ultimate goal is to enhance patients' quality of life, or 'Aging Well.' RASTEM research is not just about managing inflammation; it is about finding solutions to ensure longevity is accompanied by health. After completing the procedure in Korea, the EHL Thailand team will follow up on the recovery progress alongside medical experts, ensuring continuous care under the Advanced Regenerative Bio Act of the Republic of Korea.

Frequently asked questions

How does RASTEM differ from traditional Rheumatoid Arthritis management?

RASTEM focuses on balancing the immune system at its source using autologous stem cells, providing a regenerative approach as evaluated by the EHL team, rather than just symptomatic management or general immunosuppression.

Is care with RASTEM safe?

RASTEM uses stem cells derived from the patient's own fat, eliminating risks of immune rejection. It is produced under strict GMP standards in Korea.

What are the restoration goals for RASTEM?

The goal is to restore joint function and enhance the patient's quality of life through cellular self-repair mechanisms. RASTEM is currently in the clinical trial preparation stage. Receiving care depends on individual assessment by the EHL medical team in accordance with regenerative medicine regulations.